Genetic aspects of chronic pancreatitis

Medical Science Monitor

Volumn 10, Issue 12, 2004, Pages

  Teich, Niels ^a   Mössner, Joachim ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cationic trypsinogen; CFTR; Chronic pancreatitis; Mutation; SPINK 1

Indexed keywords

SERINE PROTEASE INHIBITOR KAZAL TYPE 1; SERINE PROTEINASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSIN INHIBITOR; TRYPSINOGEN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; CANCER RISK; CHRONIC PANCREATITIS; CLINICAL FEATURE; COHORT ANALYSIS; CYSTIC FIBROSIS; FAMILIAL DISEASE; GENE IDENTIFICATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; MUTATIONAL ANALYSIS; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; POPULATION RESEARCH; REVIEW;

CARRIER PROTEINS; CHRONIC DISEASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PANCREATITIS; POLAND; TRYPSIN; TRYPSINOGEN;

EID: 13944275585     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Etemad B, Whitcomb DC: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001; 120: 682-707
2. Witt H: Chronic pancreatitis and cystic fibrosis. Gut, 2003; 32(Suppl.2): ii31-41
3. Comfort M, Steinberg A: Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology, 1952; 21: 54-63
4. Keim V, Bauer N, Teich N et al: Clinical characteristics of patients with hereditary pancreatitis and mutations in cationic trypsinogen. Am J Med, 2001; 111: 622-26
5. Moir CR, Konzen KM, Perrault J: Surgical therapy and long-term follow-up of childhood hereditary pancrearitis. J Pediatr Surg, 1992; 27: 282-86
6. Miller AR, Nagorney DM, Sarr MG: The surgical spectrum of hereditary pancreatitis in adults. Ann Surg, 1992; 215: 39-43
7. Lowenfels AB, Maisonneuve P, DiMagno EP et al: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst, 1997; 89: 442-46
8. Ulrich CD: Pancreatic Cancer in Hereditary Pancreatitis: Consensus Guidelines for Prevention, Screening and Treatment. Pancreatology, 2001; 1: 416-22
9. Whitcomb DC, Gorry MC, Preston RA et al: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet, 1996; 14: 141-45
10. Gorry MC, Gabbaizedeh D, Furey W et al: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology, 1997; 113: 1063-68
11. Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology, 1999; 117: 7-10
12. Teich N, Bauer N, Mössner J, Keim V: Mutational screening of patients with nonalcoholic chronic pancreatitis: Identification of further trypsinogen variants. Am J Gastroenterol, 2002; 97: 341-46
13. Kukor Z, Mayerle J, Kruger B et al: Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis. Biol Chem, 2000; 277: 21389-96
14. Kukor Z, Toth M, Pal G, Sahin-Toth M: Human cationic trypsinogen. Arg(117) is the reactive site of an inhibitory surface loop that controls spontaneous zymogen activation. J Biol Chem. 2002; 277: 6111-17
15. Sahin-Toth M: Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J Biol Chem, 2000; 275: 22750-55
16. Sahin-Toth M. The pathobiochemistry of hereditary pancreatitis: studies on recombinant human cationic trypsinogen. Pancreatology, 2001; 1: 461-65
17. Sahin-Toth M, Toth M: Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun, 2000; 278: 286-89
18. Simon P, Weiss FU, Sahin-Toth M et al: Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122→Cys) that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem, 2002; 277: 5404-10
19. Szilagyi L, Kenesi E, Katona G et al: Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J Biol Chem, 2001; 276: 24574-80
20. Teich N, Ockenga J, Hoffmeister A et al: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology, 2000; 119: 461-65
21. Teich N, Bödeker H, Keim V: Cathepsin B cleavage of the trypsinogen activation peptide. BMC Gastroenterol, 2002; 2: 16
22. Teich N, Le Maréchal C, Kukor Z et al: Interaction between trypsinogen isoforms in genetically determined pancreatitis: Mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat, 2004; 23: 22-31
23. Chen JM, Le Maréchal C, Lucas D et al: "Loss of function" mutations in the cationic trypsinogen gene (PRSS1) may act as a protective factor against pancreatitis. Mol Genet Metab, 2003; 79: 67-70
24. Steer ML: Early events in acute pancreatitis. Baillieres Best Pract Res Clin Gastroenterol, 1999; 13: 213-25
25. Witt H, Luck W, Hennies HC et al: Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet, 2000; 25: 213-16
26. Witt H, Luck W, Becker M et al: Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. JAMA, 2001; 285: 2716-17
27. Chandak GR, Idris MM, Reddy DN et al: Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1) rather than the cationic trypsinogen gene (PRSS1) are significantly associated with tropical calcific pancreatitis. J Med Genet, 2002; 39: 347-51
28. Schneider A, Suman A, Rossi L et al: SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh. Gastroenterology, 2002; 123: 1026-30
29. Bhatia E, Choudhuri G, Sikora SS et al: Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology, 2002; 123: 1020-25
30. Kuwata K, Hirota M, Shimizu H et al: Functional analysis of recombinant pancreatic secretory trypsin inhibitor protein with amino-acid substitution. J Gastroenterol, 2002; 37: 928-34
31. Cohn JA, Friedman KJ, Noone PG et al: Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med, 1998; 339: 653-58
32. Sharer N, Schwarz M, Malone G et al: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med, 1998; 339: 645-52
33. Ockenga J, Stuhrmann M, Ballmann M et al: Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. Am J Gastroenterology, 2000; 95: 2061-67
34. Noone PG, Zhou Z, Silverman LM et al: Cystic fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology, 2001; 121: 1310-19
35. Audrezet MP, Chen JM, Le Marechal C et al: Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. Eur J Hum Genet, 2002; 10: 100-6
36. Chen JM, Kukor Z, Le Marechal C et al: Evolution of trypsinogen activation peptides. Mol Biol Evol, 2003; 20: 1767-77